Advertisement
FRMM vs QNRX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FRMM is a Hold and QNRX is a Hold.
Momentum Indicator for FRMM turns negative, indicating new downward trend
FRMM saw its Momentum Indicator move below the 0 level on October 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned negative. In 79 of the 85 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FRMM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for FRMM entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where FRMM's RSI Oscillator exited the oversold zone, 43 of 48 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 67 cases where FRMM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for FRMM just turned positive on October 28, 2026. Looking at past instances where FRMM's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
Following a +12.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where FRMM advanced for three days, in 175 of 206 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
FRMM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.356) is normal, around the industry mean (-1.586). P/E Ratio (-0.068) is within average values for comparable stocks, (15.399). Projected Growth (PEG Ratio) (2.780) is also within normal values, averaging (2.824). Dividend Yield (0.000) settles around the average of (0.073) among similar stocks. P/S Ratio (7.246) is also within normal values, averaging (70.854).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. FRMM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FRMM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
QNRX's Stochastic Oscillator reaching overbought zone
The Stochastic Oscillator for QNRX moved into overbought territory on October 30, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
QNRX moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for QNRX crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QNRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
QNRX broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for QNRX entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where QNRX's RSI Oscillator exited the oversold zone, 40 of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on QNRX as a result. In 63 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for QNRX just turned positive on October 23, 2026. Looking at past instances where QNRX's MACD turned positive, the stock continued to rise in 34 of 38 cases over the following month. The odds of a continued upward trend are 89%.
Following a +3.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where QNRX advanced for three days, in 176 of 213 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. QNRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.334) is normal, around the industry mean (3.162). P/E Ratio (-0.806) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QNRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
FRMM | QNRX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 61 Fair valued | 64 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 87 | 62 | |
P/E GROWTH RATING 1..100 | 12 | 100 | |
SEASONALITY SCORE 1..100 | 90 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
FRMM's Valuation (61) in the Financial Conglomerates industry is in the same range as QNRX (64) in the Biotechnology industry. This means that FRMM’s stock grew similarly to QNRX’s over the last 12 months.
FRMM's Profit vs Risk Rating (100) in the Financial Conglomerates industry is in the same range as QNRX (100) in the Biotechnology industry. This means that FRMM’s stock grew similarly to QNRX’s over the last 12 months.
FRMM's SMR Rating (100) in the Financial Conglomerates industry is in the same range as QNRX (100) in the Biotechnology industry. This means that FRMM’s stock grew similarly to QNRX’s over the last 12 months.
QNRX's Price Growth Rating (62) in the Biotechnology industry is in the same range as FRMM (87) in the Financial Conglomerates industry. This means that QNRX’s stock grew similarly to FRMM’s over the last 12 months.
FRMM's P/E Growth Rating (12) in the Financial Conglomerates industry is significantly better than the same rating for QNRX (100) in the Biotechnology industry. This means that FRMM’s stock grew significantly faster than QNRX’s over the last 12 months.
| FRMM | QNRX | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 90% | 3 days ago 89% |
| Stochastic ODDS (%) | 3 days ago 82% | 3 days ago 90% |
| Momentum ODDS (%) | 3 days ago 90% | 3 days ago 81% |
| MACD ODDS (%) | 3 days ago 82% | 3 days ago 89% |
| TrendWeek ODDS (%) | 3 days ago 79% | 3 days ago 81% |
| TrendMonth ODDS (%) | 3 days ago 90% | 3 days ago 81% |
| Advances ODDS (%) | 5 days ago 85% | 13 days ago 83% |
| Declines ODDS (%) | 3 days ago 90% | 6 days ago 90% |
| BollingerBands ODDS (%) | 3 days ago 84% | 3 days ago 90% |
| Aroon ODDS (%) | 3 days ago 90% | 3 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FRMM’s FA Score shows that 1 FA rating(s) are green while QNRX’s FA Score has 0 green FA rating(s).
- FRMM’s FA Score: 1 green, 4 red.
- QNRX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
FRMM’s TA Score shows that 5 TA indicator(s) are bullish while QNRX’s TA Score has 4 bullish TA indicator(s).
- FRMM’s TA Score: 5 bullish, 3 bearish.
- QNRX’s TA Score: 4 bullish, 6 bearish.
Price Growth
FRMM (@Packaged Software) experienced а +2.07% price change this week, while QNRX (@Biotechnology) price change was +12.01% for the same time period.
The average weekly price growth across all stocks in the @Packaged Software industry was -2.75%. For the same industry, the average monthly price growth was -3.40%, and the average quarterly price growth was -2.26%.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was -14.01%, and the average quarterly price growth was -15.33%.
Reported Earning Dates
FRMM is expected to report earnings on Nov 12, 2026.
QNRX is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Packaged Software (-2.75% weekly)Packaged software comprises multiple software programs bundled together and sold as a group. For example, Microsoft Office includes multiple applications such as Excel, Word, and PowerPoint. In some cases, buying a bundled product is cheaper than purchasing each item individually[s20] . Microsoft Corporation, Oracle Corp. and Adobe are some major American packaged software makers.
@Biotechnology (+0.20% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
FRMM and
Correlation & Price change
A.I.dvisor indicates that over the last year, FRMM has been loosely correlated with WVE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if FRMM jumps, then WVE could also see price increases.
| Ticker / NAME | Correlation To FRMM | 1D Price Change % | ||
|---|---|---|---|---|
| FRMM | 100% | -7.01% | ||
| WVE - FRMM | 44% Loosely correlated | -1.10% | ||
| PRQR - FRMM | 44% Loosely correlated | -3.47% | ||
| JSPR - FRMM | 41% Loosely correlated | -2.22% | ||
| PHUN - FRMM | 40% Loosely correlated | +0.54% | ||
| MSTR - FRMM | 38% Loosely correlated | -7.84% | ||
More | ||||